Farxiga Matches Jardiance And Cements SGLT2 Benefits In Heart Failure
AstraZeneca Drug DELIVERs At ESC
Executive Summary
Treatment with Farxiga led to an 18% reduction in a composite endpoint comprising cardiovascular death or worsening heart failure, putting it in the same ballpark as Boehringer Ingelheim and Eli Lilly's Jardiance and its 21% reduction shown in the EMPEROR-Preserved trial last year.
You may also be interested in...
Lexicon’s Sotagliflozin Succeeds In Heart Failure Following Disappointment In Diabetes
Lexicon gets broad indication across heart failure for its dual SGLT1/2 inhibitor, which will be positioned against Lilly/BI’s Jardiance and AstraZeneca’s Farxiga.
AstraZeneca To Remain In Vaccines For The Long Haul
The highs and lows experienced with its COVID-19 vaccine Vaxzevria have not deterred the UK giant from keeping a presence in the field and CEO Pascal Soriot told Scrip that the path could mirror the decade-long journey AstraZeneca had in oncology before it achieved sustained success.
AstraZeneca’s Enthusiasm For Vaccines On The Wane
As an intranasal formulation of Vaxzevria flops in a Phase I study, the attractiveness of investing any more in vaccines R&D could be wearing off for AstraZeneca.